Combination therapies, such as EBV-specific CTL with PD-1 blockade, have shown potential, as evidenced by a complete response with no evidence of disease relapse for 22 months in a metastatic EBV-positive NPC patient, suggesting potential for synergistic combination therapies (86). This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.